VOLUME 18 | NUMBER 9 | SEPTEMBER 2015 nature neurOSCIenCe a r t I C l e S MB, the most common malignant pediatric brain tumor, frequently metastasizes along the leptomeninges of the brain and spinal cord. MB is composed of four molecular and clinical subgroups (Sonic hedgehog (SHH), WNT, group 3 and group 4) [1] [2] [3] [4] . SHH-MBs represent one-quarter of all MBs, and mouse mutants with constitutive activation of the Shh pathway in the cerebella develop MBs that resemble human SHH-MBs [5] [6] [7] [8] . SHH pathway inhibitors are in clinical trials for recurrent disease 9-11 , but growth delays and resistance-induced relapse represent current challenges plaguing SHH inhibitor therapies. Given that 75% of MBs belong to non-SHH subgroups, it is crucial to identify additional actionable molecular targets. Furthermore, many MB recurrences are metastatic, and MB metastases are clinically and genetically distinct from their matched primary tumor, and will likely require metastasis specific therapies 12 . It is therefore important to explore the contribution of additional molecular targets such as ion channels toward MB tumorigenesis and metastasis to facilitate new therapeutic development.
a r t I C l e S MB, the most common malignant pediatric brain tumor, frequently metastasizes along the leptomeninges of the brain and spinal cord. MB is composed of four molecular and clinical subgroups (Sonic hedgehog (SHH), WNT, group 3 and group 4) [1] [2] [3] [4] . SHH-MBs represent one-quarter of all MBs, and mouse mutants with constitutive activation of the Shh pathway in the cerebella develop MBs that resemble human SHH-MBs [5] [6] [7] [8] . SHH pathway inhibitors are in clinical trials for recurrent disease [9] [10] [11] , but growth delays and resistance-induced relapse represent current challenges plaguing SHH inhibitor therapies. Given that 75% of MBs belong to non-SHH subgroups, it is crucial to identify additional actionable molecular targets. Furthermore, many MB recurrences are metastatic, and MB metastases are clinically and genetically distinct from their matched primary tumor, and will likely require metastasis specific therapies 12 . It is therefore important to explore the contribution of additional molecular targets such as ion channels toward MB tumorigenesis and metastasis to facilitate new therapeutic development.
Ion channels are pore-forming transmembrane proteins that regulate biological processes by controlling ion flow across the membrane.
Activation of voltage-gated potassium channels, such as EAG2, allows potassium ions to flow out of the cell. Emerging evidence has implicated altered ion channel activity in cancer and has revealed that ion channel blockers inhibit cancer cell growth in vitro [13] [14] [15] [16] . However, few studies have tested ion channel functions during tumorigenesis in animal models, and the potential therapeutic benefit of targeting ion channels in vivo to treat CNS cancers, such as MB, remains largely unexplored 17 . We sought to address these important questions.
We found that Drosophila Eag, the founding member of the mammalian potassium channel subfamily that includes EAG2, promoted tumor growth and metastasis in multiple fly brain tumor models. Our cross-species transcriptomic studies delineated common pathways regulated by the EAG2/Eag potassium channels and revealed that EAG2 and its downstream KCNT2 potassium channel cooperate in the regulation of MB cell proliferation. We found that the EAG2 channel was enriched at the trailing edge of migrating MB cells to regulate local cell volume dynamics, thereby facilitating cell motility, and EAG2 knockdown impaired MB metastasis in a xenograft model. Pharmacological a r t I C l e S inhibition of EAG2 reduced MB cell viability and motility, and we identified an FDA-approved antipsychotic drug, thioridazine, as a EAG2 channel blocker with potent efficacy in reducing intracranial xenograft MB growth and metastasis. We found that EAG2 was upregulated in a subset of MB metastases compared with the matched primary tumors from the same patients. Lastly, we present a case report of repurposing thioridazine to treat a human patient with metastasized SHH-MB.
RESULTS

Drosophila Eag promotes brain tumor growth and metastasis
Drosophila has emerged as a key model for studying brain tumors 18 . For example, overexpression of the bHLH transcriptional repressor Dpn in the neuroblast lineage leads to brain tumor formation as a result of over-proliferation of both type I and type II neuroblasts 19 . Reduced expression of the NHL domain protein brain tumor (Brat) leads to over-growth of type II neuroblasts 20 , whereas loss of the MBT domain-containing polycomb protein L(3)mbt (lethal(3) malignant brain tumor) induces over-proliferation of neuroepithelial cells in the optic lobes 21 . Notably, L3MBTL3, the human ortholog of fly L(3)mbt, is lost in a subset of human MBs with chromosome 6 deletions, and re-expression of L3MBTL3 is sufficient to suppress MB cell growth 22 . Extensive cancer research in Drosophila 23 notwithstanding, ion channel involvement in cancer has not been reported. Having found EAG2 regulation of MB tumor growth 24 , we tested for evolutionarily conserved functions of this potassium channel in cancer by generating three different Drosophila brain tumor models with or without deficiency in ether-a-go-go (eag), which encodes the fly ortholog of EAG2. Brain tumors were induced by either overexpression of dpn (dpn O/E ) or reduction of brat via RNAi knockdown (brat RNAi ) in the neuroblast lineage driven by insc-Gal4 or by loss-of-function mutation of l(3)mbt ( Fig. 1a-d ). In contrast with the normal appearance of type I and type II neuroblasts in eag mutant third instar larvae (Fig. 1e) , eag loss-of-function mutation (eag 1 ) or expression of dominantnegative eag (eag DN ) markedly reduced brain tumor growth (Fig. 1a,b and Supplementary Fig. 1a ). Although the massive tumor growth caused by dpn overexpression led to no survival of third instar larvae raised at 29 °C or adult flies raised at 25 °C (Fig. 1c) , eag deficiency reduced tumor size (Fig. 1b,d ) and enhanced survival (Fig. 1c) .
To test whether the Drosophila Eag potassium channel is involved in tumor metastasis, we adopted a standard allograft assay 25 by transplanting GFP-labeled dpn-overexpressing brain lobe tumor cells into the abdominal cavity of wild-type host flies (Supplementary Fig. 1b) . The open circulation system in flies provides a model for MB metastasis, as MB tumor cells display limited intraparenchymal invasion, but disseminate through mammalian CNS via the circulatory cerebrospinal fluid system. Not only did the transplanted GFP + brain tumor cells proliferate to fill up the abdominal cavity in 7-10 d, they also generated metastatic foci in the host brains (Fig. 1f) . Mutation of Eag, but not Shaker (Sh), potassium channel of the transplanted dpn-overexpressing brain tumors markedly reduced tumor growth and metastasis and extended the survival of host flies (Fig. 1f) . Thus, genetic suppression of Eag channel function limited tumor growth in multiple Drosophila brain tumor models and reduced metastasis in a transplantation model.
KCNT2 potassium channel involvement in MB tumorigenesis
To uncover conserved pathways downstream of human EAG2 and fly Eag potassium channels, we performed transcriptomic profiling of human MB cells with or without EAG2 knockdown and dpn-driven fly brain tumors with or without eag loss-of-function mutation, and carried out pathway enrichment analysis of significance-ranked gene lists 26 , as shown in the Enrichment Map 27 . In congruence with the effect of EAG2 knockdown on kinase signaling, mitotic cell cycle and apoptosis 24 , human MB cells with EAG2 knockdown and fly brain tumors with eag mutation displayed alterations at the transcript level in these pathways as well as those involved in nervous system development, protein catabolism, protein glycosylation and transmembrane ion transport (Fig. 2a) .
We hypothesized that an ion channel network, rather than a single ion channel such as EAG2, intricately regulates cell cycle progression via controlling cell volume dynamics. The cross-species transcriptomic analysis provided an opportunity to identify the candidate ion channel that cooperates with EAG2 during brain tumorigenesis; we therefore focused our follow-up functional studies on the single mammalian ion channel candidate among the 120 orthologous gene pairs displaying similar regulation by EAG2 knockdown in human MBs and eag mutation in fly dpn O/E brain tumors (Fig. 2a) , namely the KCNT2 gene, which encodes a potassium channel activated by intracellular sodium and chloride 28 . The KCNT2 potassium channel regulates slow afterhyperpolarization that follows bursts of action potentials, and protects against calcium-induced excitotoxicity during high-frequency neuronal firing 29 . KCNT2 expression was higher in human fetal cerebella than in adult cerebella ( Fig. 2b) and Kcnt2 was likewise expressed at higher levels in developing mouse cerebella (Fig. 2c) . Cerebellar granule neuron precursors (CGNPs) displayed enriched Kcnt2 expression compared with the cerebellar neural stem cells (NSCs) isolated from pups at postnatal day 7 (P7), whereas treating CGNPs with the Shh pathway agonist SAG increased Gli1 expression without affecting Kcnt2 (Fig. 2d) . KCNT2 was upregulated in human SHH-MB compared with other MB subgroups (Fig. 2b) , and mouse Shh-MB tumors also displayed upregulation of Kcnt2 (Fig. 2c) , consistent with its high expression in CGNPs. Moreover, KCNT2 was amplified in a variety of human cancers (Supplementary Fig. 2a) , raising the prospect of KCNT2 involvement in multiple cancers. To assess KCNT2's contribution to tumorigenesis, we treated MB cells with short hairpin RNA (shRNA) to knockdown KCNT2 (Supplementary Fig. 2b,c) or with riluzole, a blocker for the persistent sodium current that can activate KCNT2 channels 30 . Both treatments reduced MB cell growth in vitro (Fig. 2e) . KCNT2 knockdown also slowed tumor growth in vivo and prolonged survival of mice with xenograft of human Vandy-MB-11 of the SHH subgroup (Fig. 2f) . These results demonstrate the functional involvement of KCNT2 during SHH-MB tumorigenesis.
KCNT2 cooperates with EAG2 to regulate mitotic cell volume
To determine its mechanism of action, we next studied KCNT2 subcellular localization during mitosis. KCNT2 resided predominantly at intracellular compartments during interphase, but was enriched to the plasma membrane from metaphase through telophase (Fig. 3a) . Temporally, this KCNT2 enrichment to the plasma membrane overlaps with the EAG2 enrichment to the plasma membrane from late G2 to telophase 24 . However, these two potassium channels exhibited largely non-overlapping localization in these human MB cells (Fig. 3a) . Notably, both potassium channels participate in mitotic cell volume regulation that is important for MB cell proliferation. Whereas EAG2-deficient MB cells displayed cell volume increase at the interphase and late G2 phase (Fig. 3b) , leading to G2 arrest 24 , KCNT2-deficient MB cells exhibited cell volume increase at the prometaphase and metaphase, which is associated with prolonged mitosis and mitotic catastrophe (Fig. 3b,c) . We also tested whether overexpressing KCNT2 would affect COS7 cell volume and morphology. Overexpression of both EAG2 and KCNT2 decreased the cell volume to a greater extent than overexpression of EAG2, whereas overexpression of KCNT2 appeared npg a r t I C l e S to change COS7 cell morphology without reducing the overall cell volume (Fig. 3d) , indicating that KCNT2 cooperates with EAG2 to regulate the cell volume. Thus, we identified a potassium channel with a critical role in regulating MB tumorigenesis and observed a co-option mechanism for different potassium channels to control cell volume dynamics critical for mitotic success and tumor growth (Supplementary Fig. 3 ).
EAG2 involvement in MB metastasis and MB cell migration Next we asked whether EAG2, similar to Eag in Drosophila (Fig. 1f) 
; e a g 1 ( n a r t I C l e S several weeks, mice bearing MB tumors with EAG2 knockdown displayed no metastasis, even after acquiring greater tumor burden at the engraftment sites months later (Fig. 4a) . Histopathological analyses confirmed the confinement of xenografted tumors with EAG2 knockdown to the injection sites, whereas control tumors extensively disseminated to the leptomeningeal spaces (Fig. 4b) . These results demonstrate that EAG2 promotes MB metastasis, a function that is distinct from its role in driving primary tumor growth. Leptomeningeal metastasis is a cardinal feature of malignant MB with greater recurrence risk. The standard treatment of metastases with craniospinal radiation is associated with high morbidity, secondary malignancies and a severe effect on intelligence 31 . It is therefore important to pursue in vitro and in vivo studies for the development of new therapies. Critical for malignant dissemination, cell motility requires polarized morphology with lamellipodia at the leading edge and contracting cell rear at the trailing edge. Formation of these dynamic structures involves local volume changes. Although localized potassium channel activity at the trailing edge has been hypothesized to drive cell rear contraction, it is unknown whether any potassium channel is specifically localized to the trailing edge 17 . Notably, whereas EAG2 displayed an intracellular distribution distant from the plasma membrane in non-migrating MB cells, a r t I C l e S it enriched at the cell rear and localized to the trailing edge during spontaneous and directed migration ( Fig. 4c and Supplementary  Fig. 4 ). Moreover, EAG2 knockdown markedly reduced the motility of MB cells without affecting directionality, as did the EAG2 channel blocker astemizole, a known EAG2 channel blocker with an IC 50 of ~1.5 µM 32 ( Fig. 4d-f) . Although control cells exhibited polarized morphology with lamellipodia at the fan-shaped leading edge and contracting trailing edge, EAG2-deficient MB cells failed to polarize or contract the cell rear ( Fig. 4g-i) . By contrast, KCNT2 neither enriched to the trailing edge of MB cells (Supplementary Fig. 5a ) nor modulated their migratory morphology ( Supplementary Fig. 5b-d) . These findings indicate that, whereas KCNT2 and EAG2 cooperate to regulate MB cell mitosis, EAG2 functions as the primary potassium channel for the local outflow of potassium ions at the trailing edge important for MB cell motility. Thus, the beneficial effect of EAG2 knockdown or channel block is likely through a combination of two aspects: impairing MB cell mitosis by reducing the activity of EAG2 and KCNT2 and reducing MB cell motility by decreasing cell rear retraction.
Thioridazine blocks EAG2 and reduces MB tumorigenicity
To identify EAG2-blocking agents as potential MB therapeutics, we screened a series of HERG channel-blocking, FDA-approved antipsychotics for their efficacy in inhibiting MB cell growth. Based on the 5a-d and Supplementary Fig. 6 ), as did EAG2 knockdown 24 .
In contrast, D283 and GTML cells, which display lower EAG2 expression 24 , were only affected by thioridazine at higher concentrations (Fig. 5d) . Notably, treating MB cells with E-4031, a selective HERG channel blocker with nanomolar IC 50 that does not block EAG channel 33 , had little effect on MB cell growth (Fig. 5d) . Global application of thioridazine impaired human MB cell rear retraction, migratory polarization and motility ( Fig. 5e-g ), recapitulating the phenotype of EAG2 knockdown and astemizole treatment ( Fig. 4f-i) . Furthermore, local application of the EAG2 channel blocker thioridazine to the cell rear reduced the rear retraction velocity (Fig. 5h) , supporting the model that enriched EAG2 potassium channel activity at the trailing edge regulates local volume reduction to promote cell rear contraction and cell motility (Supplementary Fig. 7 ). As phenothiazines with a tricyclic ring, thioridazine and promazine are structurally (Figs. 4e and 5a, and Supplementary  Fig. 6a) . The similar effects of thioridazine, astemizole and EAG2 knockdown (Figs. 4f-i and 5d-g, and Supplementary Fig. 8a ) therefore indicate that thioridazine reduces MB cell growth and motility by blocking EAG2 channels. Moreover, thioridazine treatment of MB cells for 3 d reduced KCNT2 expression ( Supplementary  Fig. 5e ), similar to the effect of EAG2 knockdown (Fig. 2a) . Thus, it appears that thioridazine block of EAG2 potassium channel not only compromises its volume regulation crucial for human MB cell proliferation and motility, but also reduces the activity of KCNT2 potassium channel as a downstream effector of EAG2 channel activity (Supplementary Fig. 3 ).
Thioridazine reduces xenograft MB growth and metastasis As an antipsychotic for treating schizophrenia, thioridazine, a drug that has been in use for over 40 years, readily crosses the blood-brain barrier (BBB) 34 ; repetitive dosing allows micromolar plasma concentration to be achieved with widespread brain distribution in human patients 35, 36 . We tested the efficacy of intraperitoneal injections of thioridazine in treating xenograft MB tumors in mice. We began the treatment at day 26 post implantation of human MB tumor cells that expressed EAG2 at either a high (Vandy-MB-11) or low level (D283) (Fig. 6a-c) into mice, at which point the bioluminescence imaging had already demonstrated prominent tumor burden (Fig. 6d) . As expected for an EAG2 channel blocker, thioridazine (daily injection at 25 mg per kg of body weight for 2 weeks) did not affect the xenografted D283 tumors, but caused substantial tumor regression, reduced intracranial metastasis and prevented spinal cord metastasis in mice bearing human Vandy-MB-11 tumors with high EAG2 expression, thereby prolonging their survival (Fig. 6a,c) . Of the 18 mice subjected to thioridazine treatment at 25 mg per kg, two mice exhibited complete and sustained regression of both primary and metastasized Vandy-MB-11 MB tumors (Fig. 6d) . Thioridazine treatment at lower dosages (5 mg per kg or 15 mg per kg) provided less therapeutic benefit, but resulted in sustained tumor regression in one mouse in the 15 mg per kg treatment group (Fig. 6c) . Its inability to cross the BBB notwithstanding, astemizole treatment for 2 weeks reduced subcutaneous allograft of mouse MB in vivo (Supplementary Fig. 8b-d) . The ability of two structurally unrelated EAG2 channel blockers to reduce MB growth in vivo in mouse models, taken together with the specific effects of thioridazine in curbing the growth and metastasis of xenograft human MB with high, but not low, EAG2 expression, point to EAG2 as a promising target for treatment of MB that displays high EAG2 expression.
EAG2 upregulation in metastatic MB of subsets of patients
In support of the EAG2 involvement in promoting MB metastasis in human patients, quantitative PCR (qPCR) of both primary tumors and metastatic nodules (met-MBs) of molecularly subgrouped MBs from the same patients revealed that 80% (8 of 10 tumors) of the metMBs displayed >1.5-fold EAG2 upregulation compared with matched primary MBs in group 3 patients (Fig. 7a) , and 18% (2 of 11) of the met-MBs showed >1.5-fold EAG2 upregulation compared with matched primary MBs in group 4 patients (Fig. 7b) . Given that the available matched primary and metastatic human MB samples did not include SHH-MBs, we examined the Ptch +/− ; Math1-SB11; T2Onc2 Sleeping Beauty mouse model 12 using immunohistochemical analyses, and found that 37.5% (6 of 16) of metastasized Shh-MB tumors displayed higher Eag2 expression than primary tumors in the same mice (Fig. 7c) . The finding of elevated EAG2 expression in metastatic lesions raises the prospect that EAG2 may promote MB metastasis or tumor growth at the disseminated site.
Case report for thioridazine treatment of a MB patient Our studies suggest that EAG2 channel blockers that can penetrate BBB, such as thioridazine, may display therapeutic efficacy to treat npg a r t I C l e S human MB with high EAG2 expression. For this reason, we identified a 22-year-old male patient with metastatic SHH-MB and robust EAG2 expression at his iliac lesion (Fig. 8a) . This patient was initially diagnosed in 2009 with localized MB of the posterior fossa, and underwent a gross total resection followed by craniospinal irradiation therapy in combination with temozolomide. In 2011, the patient was diagnosed with relapse metastatic MB after complaining of localized knee pain, and underwent high dose chemotherapy with cisplatin, cyclophosphamide and vincristine followed by four autologous stem cell transplants. That regimen was followed with six cycles of cisretinoic acid and vorinostat. In 2012, the patient had further evidence of widespread metastasis, with immunohistochemical evidence of SHH activation, and was started on palliative chemotherapy with cycles of metronomic chemotherapy, including celebrex, vismodegib (a SHH signaling inhibitor that targets the SMO receptor) and alternating etoposide and temozolomide. Imaging demonstrated disease progression after 7.5 months of this palliative metronomic chemotherapy. At that time, the patient transferred care to our institution for consideration of an alternative therapy regimen. His iliac tumor was tested positive for EAG2 (Fig. 8a) , so thioridazine was added to the same palliative metronomic chemotherapy regimen administered thus far.
The patient received thioridazine in dose escalation for approximately 2 months, starting with 50 mg thioridazine twice daily until the dose was raised to 150 mg in the morning and 175 mg in the evening, while his other chemotherapy regimen was held constant. During initial consultation and throughout treatment, his primary brain tumor site remained in remission. Baseline transaxial fused positron emission tomography/computed tomography (PET/CT) images of the pelvis before thioridazine treatment identified a large hypermetabolic right iliac mass. Comparison with images of this region taken after the 2-month thioridazine treatment revealed a reduction of the lesion from 9.4 × 5.4 cm to 8 × 4 cm in size, and from SUVmax 13.5 to SUVmax 8.2 in FDG (fludeoxyglucose F 18) avidity, suggestive of a metabolic response to the thioridazine therapy, as all other anti-tumor medications remained unchanged throughout (Fig. 8b) . Given the known risks of HERG channel blockers in arrhythmias, tardive dyskinesia, akathisia, hepatotoxicity and leukopenia, the patient was monitored with biweekly metabolic panels, comprehensive blood counts and npg a r t I C l e S the end of the T wave in the heart's electrical cycle) prolongation or any of the above listed toxicities. However, the patient did not tolerate prolonged medication as a result of marked emotional lability and depression. Ultimately, despite trials of other chemotherapeutic regimens and radiation, the patient died of progressive disease 9 months after cessation of thioridazine treatment. The results seen in our patient are encouraging for targeting EAG2 channel as a potential therapy in MB. However, we emphasize caution given the singular case described here and considerable potential side effects that could affect tolerance of thioridazine.
DISCUSSION
MB is the most common malignant pediatric brain tumor and is a major cause of pediatric morbidity and mortality. Standard care with surgery, radiation and chemotherapy commonly results in serious cognitive and neuroendocrine deficits that can substantially affect the quality of life. Secondary malignancies resulting from metastasis or radiotherapy further compromise the prognosis. Although the 5-year survival rate for average-risk MB patients is 60-70%, the survival rate of high-risk MB patients with metastasis is 20-40% 31 . These clinical considerations underscore the urgency to identify new molecular targets and develop targeted therapies that may eventually replace nonselective chemotherapy and radiotherapy with debilitating side effects and to effectively combat metastasis. To this end, we studied ion channels, prompted by our recent finding of EAG2 function in MB cell cycle progression 24 . Using multiple Drosophila brain tumor models induced by oncogene overexpression or loss of tumor suppressors to complement our study of mice with xenografted human MB cells, we found that EAG2/Eag channel's ability to promote malignant growth and metastasis is evolutionarily conserved (Fig. 1) . Our cross-species studies identified common pathways and genes, including the SHH-MB-enriched potassium channel KCNT2, which is regulated by the mammalian EAG2 channel and fly Eag channel during tumorigenesis (Fig. 2) . Having found that KCNT2 localizes to the plasma membrane starting at metaphase, we determined that KCNT2 and EAG2 potassium channels coordinate to regulate mitotic volume, MB cell proliferation and MB tumor growth (Fig. 3) . EAG2 localized to the trailing membrane of migrating cells, where it promoted local cell volume reduction and enhanced cell motility and tumor metastatic potential (Fig. 4) . The known EAG2 channel blocker astemizole reduced MB cell migratory polarization and cell rear contraction and impaired MB cell viability, motility and allografted tumor growth (Fig. 4 and Supplementary Fig. 8) .
We identified the FDA-approved antipsychotic drug thioridazine as a EAG2 channel blocker (Fig. 5) , which demonstrated efficacy in reducing MB growth and metastasis in the CNS (Figs. 5 and 6) . We found that EAG2 was upregulated in a subset of MB metastases compared with their matched primary tumors (Fig. 7) . We further present a case report as to how repurposing this drug for treating a human patient with metastatic SHH-MB was associated with clinical response (Fig. 8) .
Evolutionarily conserved EAG2/Eag function in brain tumors
By generating multiple Drosophila brain tumor models, we found that Eag channel deficiency reduces brain tumor growth and metastasis. Our bioinformatics analyses establish a roadmap for elucidating the conserved pathways that EAG2/Eag potassium channels regulate for brain tumorigenesis. With the streamlined genome complexity in Drosophila and the ability to conduct large-scale genetic and in vivo chemical screens for anti-cancer agents 37 , our findings not only provide, to the best of our knowledge, the first example for an ion channel involvement in malignant tumor growth in Drosophila, but also stimulate investigation of ion channel functions in tumorigenesis capitalizing the powerful fly genetics.
Coordinated potassium channel regulation of tumor growth
Pronounced cell shape and volume changes accompany cell cycle progression. The proliferating cells increase volume at interphase, rapidly condense cytoplasmic volume before mitotic entry through a process known as pre-mitotic cytoplasmic condensation (PMC), reach a minimal volume at metaphase and achieve mitotic rounding, followed by volume increase and cytokinesis to generate two daughter cells 38, 39 . Having previously shown that EAG2 enriches to the plasma membrane at late G2 and M phase 24 , we found KCNT2 to be another potassium channel displaying cell cycle phase-specific plasma membrane localization critical for mitotic volume regulation (Figs. 2 and 3) . Given that KCNT2 is frequently amplified in multiple human cancers (Supplementary Fig. 2a) , the identification of specific KCNT2 channel blocker may be of high therapeutic interest.
EAG2 potassium channels for MB metastasis
Cell motility critically depends on local volume regulation. The cell volume increases at the leading edge with lamellipodia protrusion and decreases at the rear end for its retraction [40] [41] [42] . In the case of MDCK-F cells, application of the IK1 Ca 2+ -activated K + channel blocker charybdotoxin to the trailing edge inhibits migration 43 and increases cell volume 44 . However, IK1 channels are more concentrated at the cell front 45 , indicating that IK1 channels at the rear end may be preferentially activated owing to dynamic Ca 2+ oscillations in migrating cells 40, 41 . Our studies have revealed a direct mechanism employed by migrating MB cells: upregulation (Fig. 7) and translocation of EAG2 channels to the trailing edge to facilitate MB cell migration and metastasis (Fig. 4) . It is important to note that impaired cell motility might not be the sole cause underlying the metastasis defect associated with EAG2 knockdown (Fig. 4) .
Therapeutic potential of EAG2 blockers for MB treatment Ion channels are highly druggable targets, owing in large part to their membrane localization. Our finding that EAG2 channel regulates both primary MB tumor growth and metastasis provides strong impetus for considering EAG2 channel blockers as MB therapeutics. Here we provide a proof of principle use for ion channel blockers in treating brain tumors. EAG2 channel blockers with inhibitory actions on the closely related HERG channel, which regulates the repolarization phase of the cardiac action potential, may induce cardiac arrhythmia. Thus, close monitoring of the possible side effects, as has been clinically practiced for patients regularly receiving thioridazine treatment, is important. Our discovery encourages the future development of second-generation drugs with greater specificity for blocking EAG2 channels as well as substantial CNS access and better toxicity profile.
METhODS
Methods and any associated references are available in the online version of the paper.
Database accession numbers. Drosophila cell microarray GEO accession number: GSE70647. Human cell microarray GEO accession number: GSE70576. 
npg a r t I C l e S
To determine the clonogenic potential of MB cells, cells were plated at clonal density (150 cells per ml of culture medium) into 60-mm plates with indicated concentrations of astemizole or vehicle. Cell colonies were stained with 0.05% crystal violet 7-10 d after seeding. Representative results from three independent experiments were shown for all clonogenic assays. Normalized incidence of mitotic catastrophe was defined as percentage of cells with mitotic catastrophe within all the cells that entered mitosis. For the cell viability assay, 500 MB cells were seeded into one well of the 96-well plate, drugs were added 3 h after seeding and the cells were incubated for 3 d, followed by the cell viability assay using the CellTiter 96 AQueous One solution.
Immunoblotting. For Western analysis, total proteins were extracted using a lysis buffer containing 50 mM Hepes (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM dithiothreitol (DTT), 1 mM EDTA supplemented with Complete Protease Inhibitor Cocktail (Roche). Protein lysate samples, 100 µg each, were resolved on 4-12% Bis-Tris gels using MOPS buffer (Invitrogen) and transferred onto a PVDF (Millipore) membrane using a buffer containing 25 mM Tris base, pH 8.3, 192 mM glycine, and 20% methanol for 1 h at 100 V at 4 °C. Western blot assays were performed using primary antibody diluted in TBS supplemented with 0.1% Tween-20 and 0.65% milk. Immunoreactive bands were visualized using horseradish peroxidase-conjugated secondary antibodies (Amersham), followed by chemiluminescence with ECL-plus Western Blotting Detection System (Amersham).
Chemiluminescence was imaged and analyzed using Molecular Imager@ VersaDoc MP4000 system (Bio-Rad). The primary antibodies used were: rabbit anti-EAG2 (Alomone, 1:1,000, APC-053), and mouse anti-αTubulin (Sigma, 1:10,000, T6074).
three-dimensional reconstruction of cells. To visualize cell morphology and determine cell volume, we expressed soluble GFP in MB cells and performed serial imaging using our Leica TCS SP5 confocal setup. We acquired the image stacks with a Z step size at 0.17 µm per optical slice using a 63× 1.4 NA oil lens throughout the entire thickness of the cells. The confocal LIF files were converted into Imaris file through ImarisFileConverter 6.4.2. All subsequent image processing was conducted with Imaris 5.5 software. A region of interest encompassing a single cell or a local cellular region was chosen for three-dimensional reconstruction. A smooth level of 0.2 was given to every measurement for consistency. Given that EAG2 channel localizes to the plasma membrane, its capacity to permeate ion directly regulates cytoplasmic volume by controlling cytoplasmic osmolarity. We consider measuring the cytoplasmic volume a direct readout for its regulation of volume changes. To calibrate our method for volume measurement, we performed volume measurement of fluorescent spherical beads of 4 and 6 µm in diameter using the same imaging method we used for our cell studies. Our calculated volume (mean ± s.e.m.) for the 4-µm-diameter beads is 33. 61 ± 0.43 µm 3 with 95% Cl at 32.70-34.52 µm 3 , and for the 6-µm-diameter beads is 112.3 ± 1.81 µm 3 with 95% Cl at 108.5-116.1 µm 3 . The expected volume for the spherical beads of 4-and 6-µm diameters are 33.5 µm 3 and 113.1 µm 3 , respectively, which all fall in the 95% confidence interval of our calculated volumes. Given that the dimensions of MB cells are larger than 6 µm, these calibrations suggest that our imaging and volume quantification method is of sufficient accuracy for cellular comparisons. Surgical procedure for implantation of tumor cells. 5-week-old female nu/nu BALB/C immunodeficient mice were purchased from Simonsen Laboratory. Animals were housed under aseptic conditions, which included filtered air and sterilized food, water, bedding and cages. Tumor cells were implanted into the brains as previously described 24 . Briefly, mice were anesthetized by intraperitoneal injection of a mixture containing 100 mg per kg of ketamine and 10 mg per kg of xylazine in 0.9% saline. The skull of the mouse was exposed and a small opening was made using 25 gauge needle (PrecisionGuide) at 3.0 mm to the right of the midline and just behind the bregma. At this location, 10 5 Vandy-MB-11 cells in 3 µl of Hanks' Balanced Salt Solution without Ca 2+ and Mg 2+ (HBSS) was slowly injected (over 1 min) into the right caudate putamen at 3.0 mm deep from the underside of the skull. All procedures were carried out under sterile conditions.
In vivo bioluminescence monitoring. In vivo bioluminescence imaging was performed with the Xenogen IVIS Lumina System coupled LivingImage software for data acquisition (Xenogen). Mice were anesthetized with 100 mg per kg of ketamine and 10 mg per kg of xylazine and imaged 10 min after intraperitoneal injection of luciferin. Signal intensity was quantified in a region of interest over the head that was defined by the LivingImage software.
Thioridazine treatment. A 2-week daily intraperitoneal injection of thioridazine at 5, 15 or 25 mg per kg began at day 26 after tumor cell implantation when significant tumor burdens were detected. Intracranial MB tumor and metastasis were monitored with in vivo imaging before, during and after thioridazine treatment. We observed occasional weight loss in thioridazine-treated mice, and stopped the treatment in mice displaying weight loss over 15%. We observed that mice regained weight after treatment cessation.
Subcutaneous allograft and astemizole treatment. Math1-Cre; SmoM2 MB tumors were acutely extracted and minced into small tissue pieces with fine forceps in Accutase solution, followed by incubation at 37 °C for 10-20 min until the tumor tissues were dissociated into mostly single cells or small cellular aggregates under microscopic inspection. Equal volume of neural stem cell medium (neural basal medium supplemented with glutamine, N2, B27, 25 ng ml −1 basic FGF and 25 ng ml −1 human EGF without addition of serum) was added into the Accutase solution followed by spinning at 1,000 r.p.m. for 3 min. After spinning, the supernatant was removed and the tumor cells were resuspended in neural stem cell medium. Equal volume of pre-cooled Matrigel (BD Biosciences) was added into the medium to achieve a concentration of 5 × 10 6 cells per 200 µl of injection per mouse. Cell mixture was loaded into pre-cooled syringe without bubble formation. The pre-cooled needle was subcutaneously inserted into the mouse flank. It was important to sway the needle several times after insertion to create the appropriate space for tumor cells to distribute into the pocket. A total of approximately 5 × 10 6 tumor cells in 200 µl of medium were implanted.
Astemizole was purchased from Tocris Bioscience, and dissolved in OraPlus oral suspending vehicle (Paddock) with vortex and sonication to achieve stock concentration of 10 mg/ml. Once palpable tumors are detected one week post implantation, daily oral gavage of 50 mg per kg astemizole to the mice was performed for two weeks. Tumor sizes were measured daily with caliber and the tumor volume (mm 3 ) was calculated as ½ × length × width 2 (the length and width are in mm).
mice. Math1-Cre, SmoM2 and Ptch1 +/− mice are obtained from the Jackson Laboratory. 5-week-old female nu/nu BALB/C immunodeficient mice were purchased from Simonsen Laboratory. Mice were housed in an animal facility and were maintained in a temperature-controlled and light-controlled environment with an alternating 12-h light/dark cycle. A maximum of five mice were housed in one cage. All protocols were approved by the UCSF Institutional Animal Care and Use Committee. local superfusion of thioridazine to mB cells. The functional requirement of localized EAG2 channel activity for rear retraction during MB cell migration was studied by local superfusion of thioridazine. Vandy-MB-11 cells were plated on glass coverslips 4 d before experiments. The cells were maintained in DMEM medium supplemented with 10% FBS and 10 mM HEPE buffers at 37 °C during the course of drug application and imaging. Cells with clear migratory polarization (flat and extending lammelipodia, retracting cell rear) were randomly selected for superfusion of vehicle or thioridazine. Cell rear retraction was monitored under phase-contrast microscopy over a total of 12 min with 6-min intervals. For precise local superfusion, a glass pipette with tip opening diameter of 20-25 µm filled with vehicle (phosphate-buffered saline, PBS) and thioridazine (10 µM) was brought to the close vicinity of the cell rear using a micromanipulator. Pre-heated vehicle and thioridazine were constantly superfused using the PR-10 pressure regulator (ALA Scientific Instruments) at 4 kPa. A defined stream of solution was visible and applied over only the rear part of the cell. Cell rear retraction velocity was calculated by the distance of rear displacement over time (µm min −1 ). 20 randomly selected cells were studied in npg both vehicle and thioridazine group. Similar experiments were performed with thioridazine application to the front of migrating cells. electrophysiological studies. COS7 cell preparation. COS7 cells were plated on coverslips and transfected with wild type EAG2 channel. Recordings were performed 1-2 days after transfection. Cells were placed in an electrophysiology recording chamber at room temperature and bathed with (in mM) 145 NaCl, 4.8 KCl, 2 MgCl 2 , 1.1 EGTA, 10 HEPES, pH 7.2 with KOH.
Patch-clamp recordings. Whole cell patch clamp recordings were performed at room temperature, with an internal solution consisting of (in mM): 130 potassium gluconate, 10 HEPES, 1 EGTA, 2 MgCl 2 , 0.1 CaCl 2 , 4 Na 2 -ATP, 0.3 GTP, pH7.2 with NaOH. Patch electrodes (borosilicate glass) with a resistance between 3 MΩ and 8 MΩ were used; pipette and whole cell capacitance were compensated. Series resistance was less than 20 MΩ at all times and compensated >80%. Any recording in which series resistance exceeded 20 MΩ or became unstable with compensation was terminated and not used as part of the analysis. Voltage steps were given from −100 mV to +100 mV with 20 mV increments. Outward current amplitude was determined using a leak-subtracted step in voltage clamp by holding potential at +60 mV. I-V curve was generated by plotting current amplitude at different voltages.
Drosophila studies. Fly stocks. The following fly stocks were used: dpn O/E , +; insc-Gal4; UAS-dpn (ectopic expressing dpn in neuroblasts (NB) results in NB over-proliferation and brain tumor formation) 19, 51 ; eag 1 , eag 1 ; +; + (loss-offunction, expresses eag protein with truncated C-terminus) 52 ; eag DN , +; UASeag ∆932 ; + (dominant negative, ectopically expresses truncated eag protein with only 192 amino acids of the N-terminal hydrophilic domain) 53 ; brat RNAi , +; insc-Gal4/UAS-brat RNAi ; + (knockdown brat, a tumor suppressor, in NBs results in over-proliferation of mainly type II NBs and brain tumor formation) 20 ; l(3)mbt, l(3)mbt ts1 (temperature-sensitive loss-of-function allele of tumor suppressor lethal (3) malignant brain tumor, produces inactive l(3)mbt at non-permissive temperature, which results in over-proliferation and brain tumor formation) 21 ; Sh 14 , Sh 14 ; +; + (missense mutation in the core region results in non-functional shaker channel) 54 . For transplantation study, insc-Gal4; UAS-mCD8-GFP was introduced into each tested lines to visualize tumor growth. w -virgin females were used for all controls. Additional information on the function of these alleles and genes can be found in Flybase (http://www.flybase.org).
Fly culture. All larvae and flies were kept at 25 °C unless otherwise specified. For the experiments involving l(3)mbt tumor model, 29 °C was used to inactivate temperature-sensitive l(3)mbt and induce tumor formation. For insc-Gal4/UAS driven overexpression system, higher temperature promotes stronger expression of UAS-activated genes thus induces more severe phenotype. In the dpn and brat brain tumor models, 29 °C rearing condition revealed the tumor suppression efficiency of eag deficiency in a more aggressive tumor growth situation compare to 25 °C. To study the survival of dpn brain tumor animals with or without eag deficiency, around 100 larvae or flies were analyzed for each condition. The normalized incidence of survival shown in Figure 1c was defined as the percentage of larvae or flies of the indicated genotype over the number of control larvae of flies.
Drosophila immunohistochemistry and microscopy. Larval brains were dissected, fixed and stained as previously described 19 . Briefly, third instar larvae were dissected in PBS, fixed in 4% formaldehyde solution for 20 min at room temperature, and incubated with the primary antibody overnight at 4 °C and secondary antibody for 2 h at room temperature. Primary antibodies include: guinea pig anti-ase (1:5000), rabbit anti-dpn (1:500), Alexa Fluor 488 Phalloidin (Invitrogen, 1:40, A12379). Secondary antibodies conjugated to Alexa Fluor 546 (A22283) or 647 (A22287) (Invitrogen) were used at 1:400 or 1:100 respectively. Images were acquired with Leica SP5 confocal microscope. The brain lobe size was measured by Imaris 5.5 software after three-dimensional reconstruction of the z-stack of confocal images of DAPI staining. For NB quantification, type I NBs were identified by dpn + ; ase + labeling on the surface of brain lobe excluding optical lobe region, and type II NBs were identified by dpn + ; ase − labeling on the dorsal region of brain lobe. For each genotype, ten brains were analyzed.
Fly brain tumor transplantation. Tissue dissections and injections were carried out as previously described 55 . Electrophysiology glass needles with a 90-100-mm opening were used. The needle tip was further sharpened into a 45-degree angle. A pressure-injection system was made by inserting the needle into a piece of silicon tubing that had a mouthpiece at the other end. Donor GFP + , primary brain tumors or GFP + control brain lobes were retrieved from third instar larvae. The brain tissues or tumors were micro-dissected into small pieces. 4-d-old female virgin hosts were anesthetized with CO 2 and a piece of GFP + tissue was picked up with the tip of a glass needle and injected tangentially in the mid-ventral part of the abdomen. Implanted hosts were kept at 25 °C and the vials were flipped every day. Tumor growth in the abdomen and metastasis into the brain were monitored for 10 d and images were taken at day 10 post transplantation. The percentage of host flies that displayed tumor growth in the abdomens or metastasis to the brains is shown in Figure 1f . Host flies bearing transplanted tumors with eag lossof-function mutation displayed significantly reduced metastasis rate compared to the host flies bearing dpn-overexpressing tumors (P = 0.035, Student's t test). The survival of hosts was counted at daily basis until all the control flies died.
Patient treatment. The patient is a 22-year-old male with metastatic SHH-MB. The patient was initially diagnosed in 2009 with localized MB of the posterior fossa. At the time of initial diagnosis he underwent a gross total resection followed by craniospinal irradiation therapy in combination with temozolomide. The patient was subsequently followed with serial imaging. In 2011 the patient was diagnosed with metastatic MB after complaining of localized knee pain. At that time he underwent high dose chemotherapy with cisplatin, cyclophosphamide and vincristine followed by 4 autologous stem cell transplants. That regimen was followed with 6 cycles of cis-retinoic acid and vorinostat. In 2012 the patient had further evidence of widespread metastatic disease with evidence of SHH activation by immunohistochemistry. Therefore, he was started on palliative chemotherapy with alternating cycles of celebrex, temozolomide and vismodegib. At that time the patient transferred care to UCSF with informed consent for consideration of an alternative therapy regimen. Imaging demonstrated disease progression after 7.5 months of palliative chemotherapy. His iliac tumor tested positive for EAG2 and the patient was started on thioridazine in addition to the previously described palliative chemotherapy regimen. The patient received the drug in dose escalation for approximately 2 months. His other regimen was held constant over the 2-month treatment period. Initially the patient started on 50 mg thioridazine twice daily that was subsequently increased to 150 mg in the morning and 175 mg in the evening over the course of two months. At time of initial consultation and throughout treatment period, his primary brain tumor site remained in remission. As shown in Figure 8 , his iliac tumor that tested positive for EAG2 showed evidence of treatment response most likely attributable to thioridazine as none of the other anti-tumor medications had changed before and between the 2-month-interval PET/CTs. Given known risks of arrhythmias, tardive dyskinesias, akisthisia, hepatotoxicity and leukopenia, the patient was monitored with biweekly metabolic panels, comprehensive blood counts and EKGs in tandem with clinical visits and exams. The patient did not have adverse effects of QT prolongation or any of the above listed toxicities. However, the patient did not tolerate prolonged medication due to marked emotional lability and depression. Ultimately, despite trials of other chemotherapeutic regimens and radiation, the patient died of progressive disease 9 months later. The patient was not treated on a study protocol but per clinical recommendation by the treating physician. The patient signed informed consent to be treated with the regimen as outlined above.
Statistical analyses.
No statistical methods were used to pre-determine sample sizes and our sample sizes are similar to those used in other published studies. The statistical analyses were done afterwards without interim data analysis. Investigators were blinded to the group allocation for the thioridazine treatment experiments shown in Figure 6c . No data points were excluded. Two-tailed Student's t test was performed for comparison between two groups of samples. Two-way ANOVA analyses were used to assess significance of multiple data points. The Kaplan-Meier estimator and GraphPad Prism software were used to generate survival curves. Differences between survival curves were calculated using a log-rank test. The data meet the assumptions of the tests. The variance has been tested in each group of the data and the variance is similar among genotypes. Data distribution was assumed to be normal but this was not formally tested. All data were collected and processed randomly. Each experiment has been successfully reproduced at least three times and was performed on multiple days. All data are expressed as mean ± s.e.m. We considered P < 0.05 to be statistically significant.
A Supplementary methods checklist is available.
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